GENE ONLINE|News &
AstraZeneca Pledges $15 Billion China Investment and Signs Up to $18.5 Billion CSPC Obesity Deal
AstraZeneca (AZ) has recently unveiled two billion-dollar strategic moves centered on China. These include a commitment to invest $15 billion through 2030 in pioneering next-generation innovative medicines, alongside an $18.5 billion deal to secure rights to eight diabetes and weight management programs from CSPC Pharmaceuticals. (Image: GenAI)
Over the past week, AstraZeneca (AZ) unveiled two billion-dollar strategic moves centered on China. These include a commitment to invest $15 billion through 2030 in pioneering next-generation innovative medicines, alongside an $18.5 billion deal to secure rights to eight diabetes and weight management programs from CSPC Pharmaceuticals. Both announcements underscore the company’s ambition to deepen … AstraZeneca Pledges $15 Billion China Investment and Signs Up to $18.5 Billion CSPC Obesity Deal Read More » To access this post, you must purchase Individual Subscriber Yearly or Enterprise Subscriber.
GO Prime with only $1.49 now
LATEST
Alliance for Clinical Trials in Oncology Highlights Research Initiatives on World Breast Cancer Research Day
2026-08-18
European Patent Office Grants Godavari Biorefineries Patent for Anti-Cancer Drug Formulation
2026-08-18
EVENT
2026-10-20
AusBiotech 2026 (20-23 Oct, Queensland) (Australia biotech & investment)
Queensland, Australia
